Publication details

 

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Basic information
Original title:BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Authors:Pavel Šimara, Martina Peterková, Stanislav Stejskal, Michaela Potěšilová, Irena Krontorád Koutná, Zdeněk Ráčil, Filip Rázga, Tomáš Jurček, Dana Dvořáková, Jiří Mayer
Further information
Citation:
Export BibTeX
Original language:English
Field:Oncology and hematology
WWW:link to a new windowhttp://www.ncbi.nlm.nih.gov/pubmed/22233112
Type:Article in Periodical
Keywords:p-CrkL; chronic myeloid leukemia; imatinib

In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.

Related projects: